©
Getty Images (Kkolosov)
The acquisition of Dark Blue Therapeutics is expected to help accelerate the development of a new type of targeted treatment for leukaemia, with the potential to improve outcomes for patients. It is also hoped that this treatment could be expanded to other cancers.
The scientific foundations of the programmes were built on discoveries made by Oxford researchers including Oleg Fedorov, Cassandra Adams, Gilian Farnie, Kilian Huber and Paul Brennan in the Centre for Medicines Discovery; Christian Siebold in the Division of Structural Biology (STRUBI) at the Nuffield Department of Medicine; and Thomas Milne and Nicholas Crump in the MRC Weatherall Institute of Molecular Medicine at the Radcliffe Department of Medicine.
The research was further strengthened by complementary expertise across the University, including the Dunn School of Pathology, notably the groups of Professor Monika Gullerova and Professor Ivan Ahel. The work was also supported by the Structural Genomics Consortium (SGC), a global public-private partnership focused on open science.